AbbVie Q4 2025 Earnings Analysis
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
AbbVie Q4 2025 Earnings Analysis
-
Narrated by:
-
By:
About this listen
---
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown where we digest the latest corporate earnings so you don't have to. I'm Alex.
JORDAN: And I'm Jordan. Today we're diving into AbbVie's fourth quarter 2025 results, and wow, what a story this pharmaceutical giant has to tell.
ALEX: Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
JORDAN: Absolutely. Now Alex, AbbVie just delivered what CEO Robert Michael called "another excellent year," and the numbers certainly back that up. Let's start with the headline figures.
ALEX: The numbers are pretty impressive, Jordan. AbbVie hit $61.2 billion in adjusted net revenues for the full year - that's a record high and beat their initial guidance by over $2 billion. They're looking at 8.6% sales growth despite facing nearly $16 billion in HUMIRA erosion since it lost exclusivity.
JORDAN: That HUMIRA erosion is the elephant in the room, isn't it? But what's fascinating is how they've more than offset those losses. Their adjusted earnings per share came in at $10 - that's 54 cents above their initial guidance midpoint. It really shows the power of their newer drugs.
ALEX: Exactly, and speaking of those newer drugs, let's talk about the real stars of the show - SKYRIZI and RINVOQ. These two immunology powerhouses are absolutely crushing it.
JORDAN: The numbers are staggering. Combined, SKYRIZI and RINVOQ delivered about $25.9 billion in revenue - that's an $8 billion increase year-over-year. SKYRIZI alone hit $5 billion in the quarter with 31.9% operational growth, while RINVOQ came in at nearly $2.4 billion with 28.6% growth.
ALEX: And here's what caught my attention - they're already exceeding their 2027 long-term guidance by half a billion dollars. For 2026, they're projecting combined sales of over $31 billion for these two drugs. That's remarkable momentum.
JORDAN: What's really interesting is how they're dominating in specific markets. In psoriasis, SKYRIZI has over 45% prescription share in the U.S. biologic market, and their capture rates for new patients are exceeding 55% - that's four times higher than their next closest competitor.
ALEX: The competitive dynamics in IBD are particularly noteworthy. Despite new competition, SKYRIZI maintains a 75% capture rate in frontline IBD treatment, and it's even higher - 80% - specifically in Crohn's disease.
JORDAN: Now let's talk about what's really exciting for the future - their neuroscience portfolio. This segment delivered over $10.7 billion in revenue with nearly $1.8 billion in growth. But the real story here is Vialev, their Parkinson's treatment.
ALEX: Vialev hit $183 million in the quarter - up 33% sequentially - and management is now projecting it'll reach blockbuster status in 2026. That's a billion-dollar drug in its early launch phase. Pretty remarkable.
JORDAN: And they're not stopping there. They see their entire Parkinson's franchise, including Vialev, Duopa, and the upcoming Tavapadon, potentially reaching $5 billion in peak sales. Add their migraine franchise, which they also expect to exceed $5 billion, and you're talking about some serious long-term growth drivers.
ALEX: Let's shift to their pipeline because that's where AbbVie is really investing for the future. They spent nearly $1 billion more on R&D in 2025, fully funding 90 clinical programs. They also invested over $5 billion in business development.
JORDAN: Some of those acquisitions are fascinating - they picked up an in-vivo CAR-T platform, next-generation psychedelics for depression, a long-acting amylin analog for obesity, and even a novel siRNA platform. They're clearly positioning for the next decade of growth.
ALEX: Speaking of p
This episode includes AI-generated content.
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.